TriSalus Life Sciences Inc Dossier
Qualitative Analysis
Business overview
TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is an oncology-focused medical technology company dedicated to improving outcomes for patients with solid tumors. The company integrates its proprietary Pressure-Enabled Drug Delivery (PEDD) technology with standard-of-care therapies and its investigational immunotherapeutic candidate, nelitolimod (a class C Toll-like receptor 9 agonist). High intratumoral pressure and off-target delivery present major barriers to treating solid tumors in the liver and pancreas. TriSalus's FDA-cleared TriNav Infusion System utilizes PEDD to overcome these mechanical barriers, enhancing therapeutic delivery during interventional radiology procedures such as transarterial radioembolization (TARE) and transarterial chemoembolization (TACE).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Significantly expanding the commercial footprint and sales organization, including adding management layers and expanding geographic coverage to drive deeper physician engagement and platform adoption.
Expected impact: Expected to drive long-term adoption and scale the organization for its next phase of growth, despite temporary Q1 2026 revenue disruption.
Aggressively investing in foundational clinical and real-world studies to demonstrate the clinical and economic value of Pressure-Enabled Drug Delivery (PEDD). This includes the PREDICTT trial and retrospective studies in HCC.
Expected impact: Reinforces clinical and economic differentiation (such as the $7,700 per-patient charge avoidance shown in the peer-reviewed real-world study published in the Journal of Comparative Effectiveness Research) to fuel growth in 2027 and beyond.
Substantially reducing internal development spending on the nelitolimod (SD-101) immunotherapeutic program to maintain capital discipline, while consolidating Phase 1 data to secure a pharmaceutical partner.
Expected impact: Allows TriSalus to potentially monetize its therapeutic asset and mitigate late-stage clinical trial costs, while focusing internal resources on the commercial expansion of its device platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
TriSalus merged with the publicly traded SPAC MedTech Acquisition Corporation to transition into a public company, bolster its cash reserves, and fund key developmental and commercial milestones for its drug delivery technology and cancer therapies.
Financial impact: Provided a cash runway to support the commercialization of the TriNav system and clinical development of SD-101, resulting in the combined entity trading on Nasdaq under the ticker TLSI.
Strategic Partnerships
TriSalus acquired SD-101 (nelitolimod), an investigational TLR9 agonist, from Dynavax Technologies to integrate with its proprietary Pressure-Enabled Drug Delivery (PEDD) technology for treating solid tumors.
Terms: Acquisition completed on August 3, 2020.